Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-activity relationships of fluorene compounds inhibiting HCV variants.

Antiviral research - 1 Feb 2020

Kim Hee Sun, You Youngsu, Mun Jaegon, Gadhe Changdev G, Moon Heejo, Lee Jae Seung, Pae Ae Nim, Kohara Michinori, Keum Gyochang, Kim Byeong Moon, Jang Sung Key

Abstract excerpt

Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths annually. Effective direct-acting antiviral agents (DAAs) have been developed and are currently used for HCV treatment targeting the following three proteins:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Fluorenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Intracellular Signaling Peptides and Proteins

Share to Molecular Docking Simulation

Share to Structure-Activity Relationship

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 31862501
DOI: 10.1016/j.antiviral.2019.104678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-activity relationships of fluorene compounds inhibiting HCV variants.PMID 31862501Read ↗

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.Semantic proximity Read ↗

Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy.Semantic proximity Read ↗

Pharmacology Update for the Treatment of Hepatitis C Virus.Semantic proximity Read ↗

Structure-Activity Relationships in the Development of Allosteric Hepatitis C Virus RNA-Dependent RNA Polymerase Inhibitors: Ten Years of ResearchSemantic proximity Read ↗

1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.Semantic proximity Read ↗

Chemical genetics-based development of small molecules targeting hepatitis C virus.Semantic proximity Read ↗

Ligand and Structure Based Virtual Screening Strategies for Hit-Finding and Optimization of Hepatitis C Virus (HCV) InhibitorsSemantic proximity Read ↗

A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Discovery and Development of Hepatitis C Virus NS5A Replication Complex InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.